Company Profile

MediCrops Holding AG focuses on the marketing of medicinal cannabis preparations containing tetrahydrocannabinol (‘THC’). During the 2021 financial year, MediCrops founded a Swiss subsidiary, MediCrops Biomedical Technologies SA with headquarters in Yverdon-les-Bains, that will specialise in the production and processing of medicinal cannabis preparations. 
In addition,  a laboratory will be used for research purposes at the Biopôle SA research centre from June 2022.


Own production

Thanks to our own production facility in Switzerland’s largest technology centre, the Y-PARC in Yverdon-les-Bains, we can permanently guarantee the highest quality in each of our manufacturing processes.

Expanding product range

As a full-service provider in the field of medicinal cannabinoids, we want to offer doctors a wide range of high-quality therapeutic options on a permanent basis. From these, doctors can find the right preparation for each individual patient.

Delivery reliability

Ensuring continuous delivery reliability is one of our top priorities. Patients, doctors and pharmacists trust us to supply them with our products consistently and reliably.


Due to the change in the Narcotics Act in Switzerland from mid-2022, we expect a 180° turnaround of the Swiss market with strong growth and believe that our strategy will be fully vindicated.